Optimised bevacizumab biosimilar - Sinocelltech
Alternative Names: SCT-510ALatest Information Update: 23 Feb 2023
At a glance
- Originator Sinocelltech
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Wet age-related macular degeneration
Most Recent Events
- 14 Feb 2023 Phase-III clinical trials in Wet age-related macular degeneration in China (Intravitreous) (NCT05480293)
- 29 Jul 2022 Sinocelltech plans a phase III trial for Wet age-related macular degeneration (Intravitreous, Injection) in October 2022 (NCT05480293)
- 25 Sep 2020 Sinocelltech plans a phase I/II trial for Wet age-related macular degeneration in China in November 2020 (NCT04564937)